Health and Healthcare

Vindication for MannKind on FDA Approval

biotech
Thinkstock
After markets closed last Friday, MannKind Corp. (NASDAQ: MNKD) announced that the U.S. Food and Drug Administration (FDA) had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control in adults with diabetes. The FDA estimates that 25.8 million Americans have diabetes.

In early April the FDA said it would delay its decision for three months and MannKind’s stock lost 11%, dropping to around $6.15. That FDA decision followed by one week the revelation that regulators had voted nearly unanimously to approve the drug for both Type 1 and Type 2 diabetes. That news sent the stock up 80% to around $7.25.

In Friday’s announcement an FDA official noted:

Afrezza is a new treatment option for patients with diabetes requiring mealtime insulin. Today’s approval broadens the options available for delivering mealtime insulin in the overall management of patients with diabetes who require it to control blood sugar levels.

The FDA also noted that Afrezza is not a substitute for long-acting insulin. It must be used in combination with long-acting insulin in patients with type 1 diabetes. The drug is not recommended for the treatment of diabetic ketoacidosis, or in patients who smoke.

Shares traded more than 10% higher in after-hours trading on Friday and opened Monday morning up about 11.5% to post a new 52-week high of $11.48. In early trading, shares traded at $11.18, in a 52-week range of $3.80 to $11.48.

ALSO READ: Two Health Care Stocks With 50% Upside Under Obamacare

Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)

Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.

Click here now to get started.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.